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Background & Aims: Circulating platelet counts gradually decrease
in parallel with progression of chronic liver disease. Thrombocytope-
nia is a common complication of advanced liver ﬁbrosis and is
thought to be a consequence of the destruction of circulating plate-
lets that occurs during secondary portal hypertension or hypersplen-
ism. It is not clear whether thrombocytopenia itself affects liver
ﬁbrosis.
Methods: Thrombocytopenic mice were generated by disruption of
Bcl-xL, which regulates platelet life span, speciﬁcally in thrombo-
cytes. Liver ﬁbrosis was examined in thrombocytopenic mice upon
bile duct ligation. Effect of platelets on hepatic stellate cells (HSCs)
was investigated in vitro.
Results: Thrombocytopenic mice developed exacerbated liver ﬁbro-
sis, with increased expression of type I collagen a1 and a2, during
cholestasis. In vitro experiments revealed that, upon exposure to
HSCs, platelets became activated, released hepatocyte growth factor
(HGF), and then inhibited HSC expression of the type I collagen genes
in a Met signal-dependent manner. In contrast to the wild-type mice,
the thrombocytopenic mice did not accumulate hepatic platelets or
phosphorylate Met in the liver following bile duct ligation. Adminis-
tration of recombinant HGF to thrombocytopenic mice reduced liver
ﬁbrosis to the levels observed in wild-type mice and attenuated
hepatic expression of the type I collagen genes.
Conclusions: Thrombocytopenia exacerbates liver ﬁbrosis; platelets
have a previously unrecognized, antiﬁbrotic role in suppressing type
I collagen expression via the HGF-Met signaling pathway.
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E-mail address: scott.friedman@mssm.edu (S.L. Friedman).cell subsets, cytokines, and gene regulation. As a wound healing
elucidation of cellular mechanisms and the role of inﬂammatory
response to tissue injury, all the key repair elements have been
implicated in liver, yet, curiously, one classic participant has been
overlooked – until now. Platelets are ‘rapid-responders’ to tissue
injury of all types, and their aggregation and release of granule
contents have been thoroughly evaluated in vascular damage,
where they are at the nexus of therapeutic strategies. Their
recruitment to regions of acute hepatic injury, to form a provi-
sional clot, has also been well described [1,2]. In this setting,
hepatic microthrombi and increased ﬁbrin generation [3] may
promote hepatic stellate cell (HSCs) activation and ﬁbrogenesis
[4], but available data are limited.
Cirrhosis is commonly associated with a range of platelet
defects, most notably a decrease in number and function (primar-
ily hypo-aggregability) [1]. Although 78% of patientswith compen-
sated cirrhosis have platelet alterations that progressively worsen
with clinical deterioration [5], their contributions to chronic liver
injury and repair remain poorly understood [6]. Themulti-factorial
etiology of platelet dysfunction in cirrhosis has been well charac-
terized, reﬂecting splenic and splanchnic sequestration, bonemar-
row suppression, and reduced thrombopoietin (TPO) production
(Fig. 1). Yet, it has been unclearwhether progressive thrombocyto-
penia simply results from progressive ﬁbrosis, or if diminishing
platelet counts also accelerate hepatic deterioration.
When initiating hemostasis, platelets excrete their granule
contents, liberating several ﬁbrogenic inﬂammatory and angio-
genic mediators, including the platelet-derived growth factor
(PDGF) and the transforming growth factor beta 1 (TGFb1) [7].
Indeed, a single study, conducted approximately 20 years ago,
suggested that these platelet-derived factors may be promoting
hepatic ﬁbrogenesis, however, this study evaluated platelet
lysates in culture rather than using an in vivo model [8].
In contrast, recent ﬁndings have underscored a potentially
beneﬁcial role of platelets, which have been found to attenuate
liver ﬁbrosis progression through decreased expression of TGF-b
and increased expression of MMP-9 [9], as well as promoting
liver regeneration after ischemic injury [10]. Moreover, there is
a negative correlation between liver ﬁbrosis progression and
serum TPO levels in patients with cirrhosis (Fig. 2) [11]. Comple-
menting this ﬁnding, increasing platelet counts by administering
TPO agonists, is beneﬁcial in managing patients with chronic liver
disease [12,13].
With this in mind, the Kodama study [14] offers the clearest
experimental evidence to date that platelet deﬁciency may
contribute to hepatic deterioration in advanced liver disease.11 vol. 54 j 1063–1065
END-STAGE LIVER DISEASE
Bone marrow 
suppression
Deteriorated 
liver function
Portal 
hypertension
TPO Splenic sequestration
Plasma 
expansion
Platelet production Platelet destruction
Thrombocytopenia with 
   platelets in liver
FIBROGENESIS
Fig. 1. Main causes contributing to the development of thrombocytopenia
and ﬁbrosis progression in patients with cirrhosis. These include portal
hypertension with resulting hypersplenism and increased platelet destruction,
bone marrow suppression, and decrease in thrombopoietin (TPO) synthesis by the
injured liver parenchyma.
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Fig. 2. Role of platelet-released factors in liver injury. Platelets excrete
serotonin, which is implicated in hepatic regeneration following ischemia. Pro-
inﬂammatory chemokines such as CXCL4, released by activated platelets, play an
important role in intrahepatic immune cell recruitment. Angiogenesis is also
promoted by the release of the vascular endothelial growth factor (VEGF), and the
platelet-derived growth factor (PDGF). Conversely, platelets can also attenuate
liver ﬁbrosis progression through secretion of HGF and MMP9, and decreasing
expression of TGF-b.
International HepatologyThe authors generated a novel transgenic mouse with selective
knockout of the anti-apoptotic gene Bcl-xL in platelets, leading
to severe thrombocytopenia. These thrombocytopenic mice and
paired controls were subjected to liver injury by bile duct liga-
tion; transgenic, thrombocytopenic mice developed more
advanced ﬁbrosis, associated with increased production of col-
lagens a1(I) and a2(I). The authors also uncovered evidence of
bidirectional negative feedback interactions between platelets
and HSCs, the key ﬁbrogenic cell type in the liver. Speciﬁcally,
activated HSCs led to platelet activation, and platelets sup-
pressed collagen synthesis by HSCs through the release of the
anti-ﬁbrogenic cytokine, hepatocyte growth factor (HGF).
These interesting ﬁndings shed light on the surprisingly over-
looked contribution of platelet loss to liver ﬁbrosis. The model is
intriguing, yet, it remains unclear whether platelet deﬁciency
induced by loss of Bcl-xL in mice has the same impact as throm-
bocytopenia associated with progressive liver disease in patients,
particularly with respect to inﬂammatory cell interactions. More-
over, the time course of platelet loss in this model is far more
rapid than under native conditions, so that physiologic compen-
sation may not be possible. Additionally, in vivo studies were
restricted to bile duct injury, which compared to parenchymal
injury models, we now recognize as having a distinct recruitment
of ﬁbrogenic cells and the participation of both chemokines and
other inﬂammatory mediators. There may be unique interactions
between platelets and either epithelial, mesenchymal or inﬂam-
matory cells in cholestatic injury, that are not preserved in paren-
chymal liver disease. Finally, platelets have been implicated in
liver regeneration through their release of serotonin [10], yet, this
mediator was overlooked in the current studies in favor of HGF.1064 Journal of Hepatology 2011Still, it is heartening that platelets, which have always been pres-
ent in the scene of hepatic injury during disease, are now also
considered as actors in the scene.Conﬂict of interest
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